dsp-0390
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 8, 2021 (NCT05023551)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)Oc2cc(Cl)ccc2[C@@H]2OCC3(CCN(CCn4ccnc4)CC3)C[C@H]21- Mol. weight
- 415.97 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314914 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06636162 | Early Phase 1 (Phase 1) | Dec 31, 2024 | Sumitomo, Washington University in St. Louis |
| NCT05023551 | Early Phase 1 (Phase 1) | Sep 8, 2021 | Sumitomo Dainippon |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sumitomo | For profit | 1 | 0 | 1 | 2024 |
| Sumitomo Dainippon | For profit | 1 | 1 | 1 | 2021 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1